“The acquisition of EMT expands our line of single-use ProConnex flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use and systems portfolios,” said Tony Hunt, president and chief executive officer, Repligen. “The EMT portfolio also enables us to offer bioprocessing customers faster lead-times on single-use flow path solutions and to provide biopharmaceutical and CDMO customers with a more fully integrated and complete product offering in filtration and chromatography.”
Michael Pandori, co-founder, Engineered Molding Technology, said, “Over the last ten years, EMT has grown to become a key player in the supply of extruded and molded silicone products into the bioprocessing industry. We are at a transition point now where it makes sense to join forces with Repligen, who has an impressive history of scaling companies to the next level. For EMT, this means taking our products global, expanding our commercial footprint and integrating select EMT technologies into Repligen product lines while continuing to innovate.”
The proposed acquisition is expected to close during Repligen’s third quarter of 2020. Financial details were not disclosed.